WEDGE INDUSTRIAL CO.,LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 11.1 CNY | +0.27% |
|
+1.74% | -15.20% |
| Apr. 02 | Tranche Update on Wedge Industrial Co.,Ltd.'s Equity Buyback Plan announced on August 28, 2023. | CI |
| Apr. 01 | Wedge Industrial Co.,Ltd. Proposes Final Cash Dividend for 2023 | CI |
| Sales 2024 * | 1.41B 194M | Sales 2025 * | 1.84B 254M | Capitalization | 5.3B 732M |
|---|---|---|---|---|---|
| Net income 2024 * | 272M 37.55M | Net income 2025 * | 362M 49.97M | EV / Sales 2024 * | 3.76 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 2.88 x |
| P/E ratio 2024 * |
20.9
x | P/E ratio 2025 * |
15.6
x | Employees | 1,390 |
| Yield 2024 * |
1.17% | Yield 2025 * |
1.62% | Free-Float | 55.01% |
More Fundamentals
* Assessed data
More news
| 1 day | +0.27% | ||
| 1 week | +1.74% | ||
| Current month | -11.13% | ||
| 1 month | -16.29% | ||
| 3 months | +1.74% | ||
| 6 months | -8.64% | ||
| Current year | -15.20% |
1 week
10.40
11.23
1 month
10.2013.36
Current year
8.5613.36
1 year
8.5617.74
3 years
8.4820.18
5 years
8.0020.18
10 years
4.7620.18
| Managers | Title | Age | Since |
|---|---|---|---|
Tian Xiao Bi
CEO | Chief Executive Officer | 60 | 10-10-31 |
Li Yun Lin
DFI | Director of Finance/CFO | 58 | 19-03-17 |
Zhen Guang Huang
CHM | Chairman | 58 | 16-09-18 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Zhen Guang Huang
CHM | Chairman | 58 | 16-09-18 |
Tian Xiao Bi
CEO | Chief Executive Officer | 60 | 10-10-31 |
Xi Chun Yu
BRD | Director/Board Member | 62 | 21-10-21 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-22 | 11.1 | +0.27% | 2 404 823 |
| 24-04-22 | 11.07 | +1.47% | 3,206,158 |
| 24-04-19 | 10.91 | -1.53% | 3,594,903 |
| 24-04-18 | 11.08 | +1.93% | 5,134,030 |
| 24-04-17 | 10.87 | +5.53% | 4,233,704 |
End-of-day quote Shenzhen S.E., April 22, 2024
More quotes
Wedge Industrial Co Ltd is a China-based company mainly engaged in pharmaceutical manufacturing business. The Company's main businesses include the research and development, production and sales of micro-ecological live bacteria products, superalloys and products thereof. The Company also engages in metal detection and processing services. The Company's products include bifidobacterium lactobacillus triple viable bacteria tablets, vaginal lactobacillus viable bacteria capsules and probiotic dietary supplements and other micro-ecological viable bacteria products, as well as precision casting blades, superalloy powder discs, high temperature master alloys and alloy powder and other high-temperature alloy products. The Company mainly operates its businesses in the domestic and overseas markets.
Sector
Pharmaceuticals
Calendar
2024-04-28
- Q1 2024 Earnings Release
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
11.1
Average target price
-
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -15.20% | 730M | |
| +27.72% | 659B | |
| +27.68% | 557B | |
| -4.12% | 359B | |
| +16.45% | 322B | |
| +9.36% | 297B | |
| +6.30% | 215B | |
| +4.80% | 210B | |
| -6.05% | 200B | |
| -8.87% | 149B |
- Stock Market
- Equities
- 000534 Stock
